MorphoSys (MOR.DE) Stock Price
MorphoSys Price
Over the last 19 years MorphoSys grew revenue by 13.4% annually, reaching 238.28 M EUR. Earnings per share have grown at 37.0% per year over the last 16 years. For MorphoSys, the net margin of -79.6% is up versus -143.6% a few years ago.
MorphoSys stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of MorphoSys over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MorphoSys stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MorphoSys's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | MorphoSys Price |
|---|
MorphoSys Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.05 | 0.07 | 0.08 | 0.07 | 0.33 | 0.18 | 0.28 | 0.24 | 0.23 | 0.30 | 0.45 | 0.73 | 1.03 | 0.80 | 0.84 |
| 68.25 | -53.77 | 34.69 | 15.15 | -6.58 | 360.56 | -45.26 | 55.31 | -14.39 | -2.52 | 31.03 | 47.70 | 62.58 | 40.68 | -22.30 | 5.64 |
| 168.87 | 100.00 | 100.00 | 97.37 | 83.10 | 97.25 | 82.12 | 82.37 | 75.21 | 75.21 | 75.21 | 75.21 | 75.21 | 75.21 | 75.21 | 75.21 |
| 179.00 | 49.00 | 66.00 | 74.00 | 59.00 | 318.00 | 147.00 | 229.00 | 179.00 | 174.49 | 228.64 | 337.69 | 549.03 | 772.41 | 600.18 | 634.02 |
| 21.00 | -59.00 | -68.00 | -60.00 | -108.00 | 17.00 | -256.00 | -220.00 | -250.00 | -190.00 | -112.00 | -16.00 | 289.00 | 411.00 | 29.00 | 53.00 |
| 19.81 | -120.41 | -103.03 | -78.95 | -152.11 | 5.20 | -143.02 | -79.14 | -105.04 | -81.90 | -36.84 | -3.56 | 39.59 | 40.02 | 3.63 | 6.29 |
| 14.00 | -60.00 | -69.00 | -56.00 | -103.00 | 97.00 | -514.00 | -151.00 | -189.00 | -148.00 | -113.00 | -40.00 | -50.00 | 169.00 | 22.00 | 40.00 |
| -566.67 | -528.57 | 15.00 | -18.84 | 83.93 | -194.17 | -629.90 | -70.62 | 25.17 | -21.69 | -23.65 | -64.60 | 25.00 | -438.00 | -86.98 | 81.82 |
| 26.24 | 26.13 | 29.00 | 31.53 | 31.60 | 32.72 | 34.14 | 34.17 | 39.56 | 39.56 | 39.56 | 39.56 | 39.56 | 39.56 | 39.56 | 39.56 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales MorphoSys generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MorphoSys retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MorphoSys's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares MorphoSys has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MorphoSys's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
MorphoSys stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys business model & stock analysis
MorphoSys SWOT Analysis
Strengths
MorphoSys AG possesses several key strengths that contribute to its competitive advantage in the industry. Firstly, the company has a strong portfolio of innovative and proprietary technologies, such as its antibody and protein engineering platform, which enables the discovery and development of novel therapeutic antibodies. This technology leadership allows MorphoSys to differentiate itself from competitors and attract collaborations and partnerships.
Secondly, MorphoSys has established a robust pipeline of drug candidates across various therapeutic areas, including oncology, immunology, and inflammation. This diversified portfolio minimizes the company's dependency on a single product and provides opportunities for growth and revenue diversification.
Additionally, the company benefits from strong intellectual property rights and a solid track record in obtaining and defending its patents. This provides MorphoSys with a strong barrier to entry and protection against potential competitors.
Weaknesses
Despite its strengths, MorphoSys AG also faces certain weaknesses. One of the primary concerns is the company's heavy reliance on collaborations and partnerships for the development and commercialization of its drug candidates. This leaves MorphoSys vulnerable to potential delays or disruptions in these collaborations, which could impact its pipeline and revenue streams.
Furthermore, the company's financial performance has been inconsistent, with fluctuations in revenue and profitability over the years. This can be attributed to the high costs associated with research and development activities, as well as the uncertainty surrounding the success and market acceptance of its drug candidates.
Opportunities
MorphoSys AG operates in a rapidly evolving and growing biopharmaceutical industry, which presents several opportunities for the company. The increasing prevalence of complex diseases, such as cancer and autoimmune disorders, offers a significant market potential for innovative therapeutic solutions developed by MorphoSys.
Moreover, advancements in technology and scientific understanding provide opportunities for the company to expand its capabilities and develop novel treatment approaches. This includes areas like personalized medicine and immuno-oncology, where MorphoSys can leverage its expertise in antibody engineering to develop targeted and more effective therapies.
Threats
In addition to opportunities, MorphoSys AG also faces certain threats in the industry. One of the primary threats is the intense competition from both large pharmaceutical companies and emerging biotechnology firms. This competition can result in pricing pressure, limited market access, and the potential for rivals to develop similar or superior therapies.
Furthermore, regulatory uncertainties and challenges in obtaining approvals for new drugs pose a significant threat to MorphoSys. Compliance with stringent regulations and the risk of delays or rejections by regulatory bodies can impact the company's ability to bring its products to market in a timely manner.
MorphoSys Segments
MorphoSys Revenue by Region
3 Years
Max
Details
MorphoSys Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
MorphoSys historical P/E ratio, EBIT multiple, and P/S ratio
MorphoSys annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
MorphoSys shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
MorphoSys stock splits
MorphoSys Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/16/2022 | -1.53EUR | - | 68.52 MEUR | - | 2022 Q3 |
| 8/3/2022 | -1.94EUR | - | 58.82 MEUR | - | 2022 Q2 |
| 5/4/2022 | -1.87EUR | - | 47.30 MEUR | - | 2022 Q1 |
| 3/16/2022 | -2.79EUR | - | 47.11 MEUR | - | 2021 Q4 |
| 11/10/2021 | -2.58EUR | - | 39.53 MEUR | - | 2021 Q3 |
| 7/28/2021 | -1.95EUR | - | 35.07 MEUR | - | 2021 Q2 |
| 5/5/2021 | -1.39EUR | - | 46.22 MEUR | - | 2021 Q1 |
| 3/15/2021 | -2.16EUR | - | 33.98 MEUR | - | 2020 Q4 |
| 11/11/2020 | -1.87EUR | - | 19.56 MEUR | - | 2020 Q3 |
| 8/5/2020 | -1.57EUR | - | 10.73 MEUR | - | 2020 Q2 |
EESG©
Eulerpool ESG Scorecard© for the MorphoSys stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
MorphoSys shareholder structure
| % | Name |
|---|---|
109.91972% | |
0.03180% | |
0.02702% | |
0.01571% | |
0.00262% | |
0.00166% |
MorphoSys Executives and Management Board
15 members · avg. age 60 · 53 % women
Dr. Jean-Paul Kress (58)
Chairman of the Management Board, Chief Executive Officer
4.65 M EUR
Management
Ms. Lucinda Crabtree (44)
Chief Financial Officer, Member of the Management Board
Ms. Maria Castresana
Senior Vice President - Global Head of Human Resources, Member of the Executive Committee
Ms. Luisa Ciccarelli
Senior Vice President - Global Head of Technical Operations, Member of the Executive Committee
Mr. Joe Horvat
General Manager, Member of the Executive Committee
Mr. Tim Demuth
Member of the Executive Committee, Chief Research and Development Officer
Ms. Barbara Krebs-pohl
Member of the Executive Committee, Chief Business Officer
Board of Directors
Dr. Marc Cluzel (67)
Independent Chairman of the Supervisory Board · since 2012
Dr. George Golumbeski (65)
Independent Deputy Chairman Member of the Supervisory Board · since 2018
Mr. Michael Brosnan (68)
Independent Member of the Supervisory Board
Mrs. Krisja Vermeylen (61)
Independent Member of the Supervisory Board
Ms. Sharon Curran (54)
Independent Member of the Supervisory Board
Mr. Andrew Cheng
Independent Member of the Supervisory Board
MorphoSys Supply Chain
MorphoSys Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.51 | 0.49 | 0.86 | ||
| 2 | 0.87 | 0.95 | 0.68 | ||
| 3 | 0.85 | 0.44 | 0.43 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.05 | 0.28 | — | ||
| 2 | 0.53 | -0.75 | -0.89 | ||
| 3 | -0.60 | -0.30 | -0.80 | ||
| 4 | 0.34 | -0.41 | -0.74 | ||
| 5 | 0.94 | 0.64 | -0.60 |
Frequently asked questions about MorphoSys
MorphoSys AG operates under a differentiated business model in the biopharmaceutical industry. The company specializes in developing novel therapeutic antibodies to address unmet medical needs. Leveraging its proprietary technology, MorphoSys AG focuses on discovering and optimizing antibodies at an early stage, enabling the development of potential treatments for various diseases, including cancer and autoimmune disorders. By collaborating with pharmaceutical partners and licensing its innovative antibodies, MorphoSys AG generates revenue through upfront payments, milestone-related royalties, and product sales. This business model helps the company capitalize on its expertise in antibody development and create value through its diverse portfolio of potential therapies.
MorphoSys AG operates primarily in the biotechnology and pharmaceutical industries.
The main competitors of MorphoSys AG in the market include biotechnology companies such as Roche Holding AG, Amgen Inc., and Gilead Sciences Inc.
MorphoSys AG is a renowned biopharmaceutical company headquartered in Germany. It was founded in 1992 and has since established itself as a global leader in the field of therapeutic antibodies. The company specializes in developing innovative drugs to address unmet medical needs. MorphoSys AG utilizes its unique technology, known as HuCAL (Human Combinatorial Antibody Library), which enables the efficient discovery and optimization of fully human antibodies. With a focus on oncology and autoimmune disorders, MorphoSys AG has successfully collaborated with numerous pharmaceutical partners to bring novel treatments to patients worldwide. The company's commitment to scientific excellence and dedication to improving human health has propelled its growth and reputation in the industry.
Some significant milestones achieved by MorphoSys AG include the successful development and approval of several innovative antibodies and their subsequent commercialization. The company's antibody MorphoSys-derived was the first fully human therapeutic antibody to receive marketing approval in the European Union. MorphoSys AG has also entered into strategic partnerships with various pharmaceutical companies, expanding its pipeline and driving strong financial growth. Furthermore, the company received FDA approval for its antibody, marketed as Monjuvi, for the treatment of certain lymphoma cancers. These milestones demonstrate MorphoSys AG's dedication to advancing novel therapies and its position as a leader in the field of antibody-based therapeutic development.
MorphoSys AG is primarily present in various countries and regions across the globe. The company has a significant presence in Germany, where its headquarters are located. Additionally, MorphoSys AG has established a strong presence in the United States, with offices in the state of Massachusetts. Furthermore, the company has expanded its reach to other key markets, including the United Kingdom, Switzerland, Austria, and other European countries. With its global footprint, MorphoSys AG has successfully penetrated multiple international markets, solidifying its presence in the biotechnology and pharmaceutical industries.
MorphoSys AG represents values of innovation, collaboration, and scientific advancement in the biotechnology industry. As a leading company, MorphoSys focuses on developing therapeutic antibodies to address unmet medical needs. With their corporate philosophy centered around cutting-edge science and a patient-centric approach, MorphoSys aims to improve the lives of patients worldwide. By employing their unique proprietary technology, they continually strive to advance the field of antibody research and development. Through their commitment to excellence and passion for transforming healthcare, MorphoSys AG stands as a progressive and influential player within the biotech sector.
12 analysts currently rate the MorphoSys stock: 5 recommend buying, 7 holding and 0 selling. For 2026, analysts expect MorphoSys to generate revenue of 449.11 M EUR and earnings per share of -1.03 EUR.
The MorphoSys share (MOR.DE) is listed on 13 stock exchanges, including: NASDAQ (MPSYF), XETRA (MOR.DE), Frankfurt (MOR.F), München (MOR.MU), Stuttgart (MOR.SG), Düsseldorf (MOR.DU), Berlin (MOR.BE), Hamburg (MOR.HM).
MorphoSys AG is a biopharmaceutical company headquartered in Planegg near Munich. It was founded in 1992 and has been listed on the stock exchange since 1999. MorphoSys's business model is focused on developing and bringing to market new and innovative therapies for cancer and other serious diseases. MorphoSys focuses on the discovery, development, and commercialization of therapeutic antibodies - proteins specifically targeting certain structures in the body. The company's main products are the antibody therapeutics Tremfya® and Monjuvi®, used for the treatment of skin and blood cancers. Some of the areas in which MorphoSys operates include antibody research and conducting clinical studies, licensing technologies and know-how, selling licenses and patent rights, as well as collaborating with other pharmaceutical and biotech companies to develop new therapies. MorphoSys has a broad portfolio of antibodies and technologies based on its in-house HuCAL® antibody technology. This technology allows for the production of antibodies against almost any desired target structure in the body. MorphoSys also works with partners to utilize this technology in the development of new therapies in multiple areas, including oncology (cancer treatment), inflammatory and infectious diseases, and autoimmune diseases. MorphoSys also has its own clinical development department, which focuses on conducting clinical studies to evaluate the safety and efficacy of antibody therapeutics. The company has several clinical development programs in oncology and other therapeutic areas, and works closely with other partners to develop and bring new therapies to market. MorphoSys also offers various services related to the HuCAL® technology, including the creation of antibody libraries, on-demand antibody production, and antibody optimization for specific applications. The company also has a platform for antibody engineering technology called Ylanthia®, which allows for the development of specific antibodies for clients. Overall, MorphoSys's business model is based on the research, development, and commercialization of innovative antibody-based therapies. The company's divisions include research, clinical development, marketing, and technology licensing. The company is well positioned to unlock the potential of new therapies and grow in the biopharmaceutical products market.
The expected revenue of MorphoSys is 449.11 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of MorphoSys is -40.89 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for MorphoSys at the moment.
The P/S cannot be calculated for MorphoSys currently.
The Eulerpool Quality Score for MorphoSys is 2/10.
The ISIN of MorphoSys is DE0006632003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of MorphoSys is 663200. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of MorphoSys is MOR.DE. The ticker symbol is used to trade MorphoSys shares on the stock exchange.
MorphoSys is assigned to the 'Health' sector.
The dividends of MorphoSys are distributed in EUR.
MorphoSys stock
MorphoSys Peer Group
MorphoSys Ticker
MorphoSys FIGI
All fundamentals and in-depth analysis of MorphoSys
Our stock analysis for MorphoSys stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MorphoSys. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.